ESTRO 2024 - Abstract Book

S2522

Clinical - Urology

ESTRO 2024

Regarding GU and GI toxicity none out of 12 patients reported toxicity more than grade 1. See figure 1 for a detailed bar chart regarding toxicity scores for all patients.

Conclusion:

Current preliminary data suggests that a PTV-margin of 5 mm is sufficient to cover the SV when using online adaptation together with intra-fraction fiducial tracking. The treatment is very well tolerated, with a toxicity profile comparable to or even better than reported in the STAMPEDE trial [1]. These preliminary data from the UPRATE trial can be considered a successful first step towards ultra-hypofractionation for high-risk PCa patients when including the entire SV in the target volume.